Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”), a holding subsidiary of the company, recently received an approval number from the US Food and Drug Administration (FDA) for diltiazone hydrochloride tablets. This drug is mainly used to treat chronic stable angina pectoris and angina caused by coronary artery spasms. This approval indicates that Yichang Renfu is qualified to sell this product in the US market, which will have a positive impact on the company's expansion of the US generic drug market. In the future, Yichang Renfu will actively advance preparations for the launch of this product in the US market.

Zhitongcaijing · 2d ago
Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”), a holding subsidiary of the company, recently received an approval number from the US Food and Drug Administration (FDA) for diltiazone hydrochloride tablets. This drug is mainly used to treat chronic stable angina pectoris and angina caused by coronary artery spasms. This approval indicates that Yichang Renfu is qualified to sell this product in the US market, which will have a positive impact on the company's expansion of the US generic drug market. In the future, Yichang Renfu will actively advance preparations for the launch of this product in the US market.